Form 4 for NDRA ENDRA Life Sciences Inc.
Accepted 2022-05-19 00:00:00 ET · period of report 2022-05-17 · accession 0001209191-22-030307 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-19 | 2022-05-17 | NDRA | Michelon Francois Roger | CEO, Dir | P - Purchase | $0.19 | +5,100 | 97.2K | +6% | +$969 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-17 | P | A | 5,100 | $0.19 | 97,191 | D | — | — |